Treatment of Age-related Macular Degeneration

The immune stimulatory compound used as anticancer therapy also showed strong anti-angiogenesis effectiveness. This can be shown by reduction of blood vessel formation. A new application for this compound is the age-related macular degeneration (AMD), which has been shown to respond well to antiangiogenesis compounds such as an inhibitor of angiogenesis (Lucentis), which targets the vascular endothelial growth factor (vEGF) receptor. The second compound is Avastin, which has not been approved against AMD but colon cancer only. Direct application of the compound into the eye is required and acceptable as therapy. Our compound is long-lasting and maybe superior because of its low frequency of application. Furthermore it may have less side-effects.

Contract companies are known and can be asked to characterize the efficacy and toxicity of the compound in a validated AMD eye animal model. This is required for further development of the compound.

Time to clinical trials is 2 to 3 years Clinical grade GMP material for clinical trials is already available.

One patent is issuded, another Patent application pending